EUVIMEDEUVIMED entdecken
Crossref

Guillain-Barre Syndrome

Alejandro A. Rabinstein

The Open General & Internal Medicine Journal · 2007

DOI: 10.2174/1874076600701010013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Open General & Internal Medicine Journal, 2007. Verfasst von Alejandro A. Rabinstein. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guillain-Barré syndrome (GBS) is caused by an inflammatory polyradiculoneuropathy, which most commonly results from acute demyelination produced by a CD4 T-cell mediated response against myelin proteins.Axonal forms have also been recognized.Molecular mimicry between components of the bacterial wall of Campylobacter jejuni and gangliocytes in the membranes of peripheral axons may be responsible for some cases of axonal GBS.Immune therapy with plasma exchange or intravenous immunoglobulin is the standard of care for the treatment of patients with acute GBS.This review summarizes available information regarding the pathophysiology, clinical manifestations, therapeutic considerations, and prognosis of this disorder.Guillain-Barré syndrome (GBS, or better Guillain-Barré-Strohl syndrome to recognize the three authors responsible for the first description of this disorder) [1] is an inflammatory polyradiculoneuropathy characterized by the acute development of diffuse weakness and areflexia.This syndrome encompasses various subtypes, the most common of which is acute inflammatory demyelinating polyradiculoneuropathy (AIDP).Less common are the axonal variants, acute motor axonal neuropathy (AMAN) and acute motor and sensory axonal neuropathy (AMSAN), and the atypical forms with more localized clinical expressions such as the Fisher syndrome [2].AIDP is responsible for most cases of GBS in the United States and Europe [3,4].Axonal forms are more common in China, Japan, and perhaps Central America [5,6]. EPIDEMIOLOGYMost population-based studies report an incidence of 1.2 and 1.9 cases of GBS in 100,000 individuals per year [2,4].The incidence tends to increase steadily with age.Men are affected slightly more often than women.Most cases are sporadic and exceed a relatively stable incidence in the population over the years.However, epidemic outbreaks of cases of GBS have been reported, most notably, summer outbreaks in China linked to contamination of water by Campylobacter jejuni [5,7].Preceding infections are noted in nearly two-thirds of patients with GBS [8,9].Implicated microorganisms include Campylobacter jejuni, cytomegalovirus, Epstein-Barr virus, Haemophilus influenza and Mycoplasma pneumoniae.Immunizations with vaccines have been linked with recurrence of GBS.Over the last two decades there has been a steady decline in the number of cases of GBS related to influenza vaccine.The risk of developing GBS as a complication of influenza of vaccine at the present time is no larger than 1: 1,000,000 [10].Rabies vaccine containing brain material may result in GBS in 1: 1,000 immunizations.There is no convincing evidence that any other vaccines carry a risk of

Zitieren

APA

Rabinstein, A. A. (2007). Guillain-Barre Syndrome. The Open General & Internal Medicine Journal. https://doi.org/10.2174/1874076600701010013

Vancouver

Rabinstein AA. Guillain-Barre Syndrome. The Open General & Internal Medicine Journal. 2007. doi:10.2174/1874076600701010013

BibTeX
@article{Rabinstein2007,
  author = {Rabinstein, Alejandro A.},
  title = {Guillain-Barre Syndrome},
  journal = {The Open General & Internal Medicine Journal},
  year = {2007},
  doi = {10.2174/1874076600701010013}
}
Kostenlos starten →